AMEERA-3, a phase 2 trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (her2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies

Tolaney S., ÇİÇİN İ., Betancourt R., Chan A., Kaen D., Kaufman P., ...Daha Fazla

San Antonio Breast Cancer Virtual Symposium, ELECTR NETWORK, 8 - 11 Aralık 2020, cilt.81, (Özet Bildiri) identifier

  • Yayın Türü: Bildiri / Özet Bildiri
  • Cilt numarası: 81
  • Basıldığı Ülke: ELECTR NETWORK
  • Trakya Üniversitesi Adresli: Evet